FocalTherics
FOCL Healthcare Medical Distribution
FocalTherics' revenue for fiscal 2025 (year ended December 2025) was $70.5 million, up 1.63% from fiscal 2024. In the quarter to June 2026, revenue grew 38.9%, EPS fell 129.4%, free cash flow grew 21.5% and total debt rose 366.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
Follow FOCL
FocalTherics (FOCL) EV/Sales
As of 16 October 2026, FocalTherics (FOCL) trades at a EV/Sales of 2.1×. Over the past ten years it has ranged from 0.5× (April 2025) to 6.4× (May 2023); the current reading is higher than 50% of that period. That is above the Medical Distribution industry median of 0.6× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.8× | 95.55% |
| FY2024 | 0.9× | (61.64%) |
| FY2023 | 2.4× | (53.79%) |
| FY2022 | 5.1× | 80.04% |
| FY2021 | 2.8× | 6.47% |
| FY2020 | 2.7× | 20.63% |
| FY2019 | 2.2× | 168.45% |
| FY2018 | 0.8× | (49.66%) |
| FY2017 | 1.6× | (14.74%) |
| FY2016 | 1.9× | (29.93%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.6× | 29.36% |
| Mar 2026 | 2.0× | 13.43% |
| Dec 2025 | 1.8× | 36.36% |
| Sep 2025 | 1.3× | 52.80% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| HKPD Cellyan Biotechnology Co., Ltd compare | n/m |
| YI 111, Inc. Sponsored ADR compare | 0.0× |
| CAH Cardinal Health, Inc. compare | 0.3× |
| COSM Cosmos Health Inc. compare | 0.4× |
| ACH Accendra Health, Inc. compare | 0.9× |
| HSIC Henry Schein, Inc. compare | 0.9× |
| SNYRQ Synergy CHC Corp. compare | 0.9× |
| AHG Akso Health Group Sponsored ADR compare | 1.8× |
| FOCL FocalTherics | 2.1× |
| Medical Distribution industry median | 0.6× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)